(UroToday.com) African American men (AAM) have a higher incidence and mortality from prostate cancer, but disease-specific outcomes may be identical if there is a timely diagnosis, appropriate staging, and equitable and adequate treatment delivered. Disease risk-stratification by the NCCN only includes certain clinical parameters and does not capture underlying tumor biology or genomic diversity. Dr. Kosj Yamoah and colleagues here report their work to understand if the Decipher genomic classifier, which to date has been validated in multiple cohorts largely comprised of White men, can be validated to define high-risk patients in AAM with clinically localized prostate cancer.